HONOLULU (March 16, 2019) ─ Results from a recent clinical trial show that a new immunotherapy treatment, when added to standard chemotherapy, significantly prolongs survival in women with recurrent ovarian cancer. The randomized phase II trial compared overall survival of women who received chemotherapy with and without immunotherapy for recurrent ovarian cancer. Women treated with a combination of chemotherapy and immunotherapy experienced significantly prolonged survival.

https://www.sgo.org/newsroom/news-releases/immunotherapy-improves-prognosis-for-women-with-recurrent-ovarian-cancer-in-clinical-trial/